Surgery Partners Q1 revenue up 7.7% to $717.4M, Adjusted EBITDA $97.5M; raises FY outlook

Surgery Partners, Inc.

2024-Q1 EPS reported -$0.10 revenue$717,400,000

Net loss $12.4M; Adjusted EBITDA $97.5M (+8.2% YoY); margin 13.6%.
Same-facility revenue +10.2% YoY with 8.8% revenue per case increase and 1.3% case growth.
FY 2024 guidance raised: revenue at least $3.05B, Adjusted EBITDA at least $505M.
Completed refinancing of term loan and unsecured notes; no material debt maturities until 2030.
Cash $185.2M; revolver capacity $607.3M; net debt/EBITDA ratio ~3.5x.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surgery Partners, Inc. reported full year 2024 results: revenue at least $3.05 billion. Guidance raised.

Period: full year 2024
Revenue: at least $3.05 billion
Guidance: raised
Result: guidance update

Exact text from the filing

The Company raised its outlook for 2024 revenues to be at least $3.05 billion and projects 2024 Adjusted EBITDA to be at least $505 million.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surgery Partners, Inc. reported three months ended March 31, 2024 results: revenue $717.4 million, net income -$12.4 million.

Period: three months ended March 31, 2024
Revenue: $717.4 million
Net income: -$12.4 million
Result: reported results

Exact text from the filing

• Revenues increased 7.7% to $717.4 million compared to the prior year period ◦ Same-facility revenues increased 10.2% • Net loss attributable to Surgery Partners, Inc. was $12.4 million

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Surgery Partners, Inc. filing history →

Source: SEC EDGAR

accession 0001638833-24-000110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.